Wire · opportunities
FDA Approves Finerenone (Kerendia) for CKD and Type 1 Diabetes
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 17 September 2026 · Fusion42 review
The FDA has approved finerenone (Kerendia) to reduce urinary albumin-to-creatinine ratio in adults with chronic kidney disease associated with type 1 diabetes, marking the first new treatment option for this condition in over 30 years. This approval is based on the FINE-ONE trial demonstrating a 28% reduction in albuminuria at six months and is expected to reduce the risk of sustained kidney function decline and end-stage kidney disease.
This Wire brief sits within Fusion42's coverage of Biotech, and 5 sources have reported it between 17 Sep 2026 and 22 Sep 2026.
◆ ◆ The Wire takeaway
Finerenone's FDA approval opens a rare treatment pathway for type 1 diabetes-related kidney disease, creating immediate opportunities for drug developers and care providers to target a historically underserved patient group. Your clinical or biotech venture can now claim a foothold where competitors have not entered for decades.
◆ Coverage
5 sources · first reported 17 Sep 2026 · latest 22 Sep 2026
◆ Related on Wire
◆ Topics